A3P Biomedical AB Sustainability Reports
A3P Biomedical AB develops advanced diagnostic solutions for prostate cancer. Its primary product is Stockholm3, a clinically validated blood test used for early and precise detection of aggressive prostate cancer.
Sector: Professional & technical services
Country: Sweden
Exchange: Unlisted
LEI: 9845003BE13F8F6CVF78
1 reports from 2025 to 2025
